Axcella Health Competitors

Aligos Therapeutics (NASDAQ:ALGS) and Axcella Health (NASDAQ:AXLA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares Aligos Therapeutics and Axcella Health's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Aligos Therapeutics and Axcella Health, as provided by MarketBeat.com.

Aligos Therapeutics presently has a consensus target price of $30.50, indicating a potential upside of 41.60%. Axcella Health has a consensus target price of $17.1250, indicating a potential upside of 210.80%. Given Axcella Health's higher probable upside, analysts plainly believe Axcella Health is more favorable than Aligos Therapeutics.

Valuation and Earnings

This table compares Aligos Therapeutics and Axcella Health's top-line revenue, earnings per share (EPS) and valuation.

Institutional and Insider Ownership

66.8% of Axcella Health shares are owned by institutional investors. 10.4% of Axcella Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Axcella Health beats Aligos Therapeutics on 4 of the 7 factors compared between the two stocks.

Cellectis (NASDAQ:CLLS) and Axcella Health (NASDAQ:AXLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Volatility and Risk

Cellectis has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500. Comparatively, Axcella Health has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Profitability

This table compares Cellectis and Axcella Health's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cellectis and Axcella Health, as provided by MarketBeat.

Cellectis currently has a consensus price target of $24.25, indicating a potential upside of 25.58%. Axcella Health has a consensus price target of $17.1250, indicating a potential upside of 210.80%. Given Axcella Health's stronger consensus rating and higher probable upside, analysts clearly believe Axcella Health is more favorable than Cellectis.

Earnings & Valuation

This table compares Cellectis and Axcella Health's top-line revenue, earnings per share and valuation.

Axcella Health has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Axcella Health, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

33.3% of Cellectis shares are owned by institutional investors. Comparatively, 66.8% of Axcella Health shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 10.4% of Axcella Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Axcella Health beats Cellectis on 7 of the 13 factors compared between the two stocks.

TCR2 Therapeutics (NASDAQ:TCRR) and Axcella Health (NASDAQ:AXLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Volatility and Risk

TCR2 Therapeutics has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500. Comparatively, Axcella Health has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Profitability

This table compares TCR2 Therapeutics and Axcella Health's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for TCR2 Therapeutics and Axcella Health, as provided by MarketBeat.

TCR2 Therapeutics currently has a consensus price target of $39.2857, indicating a potential upside of 63.28%. Axcella Health has a consensus price target of $17.1250, indicating a potential upside of 210.80%. Given Axcella Health's higher probable upside, analysts clearly believe Axcella Health is more favorable than TCR2 Therapeutics.

Earnings & Valuation

This table compares TCR2 Therapeutics and Axcella Health's top-line revenue, earnings per share and valuation.

TCR2 Therapeutics is trading at a lower price-to-earnings ratio than Axcella Health, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

82.1% of TCR2 Therapeutics shares are owned by institutional investors. Comparatively, 66.8% of Axcella Health shares are owned by institutional investors. 28.0% of TCR2 Therapeutics shares are owned by company insiders. Comparatively, 10.4% of Axcella Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

TCR2 Therapeutics beats Axcella Health on 7 of the 11 factors compared between the two stocks.

Sutro Biopharma (NASDAQ:STRO) and Axcella Health (NASDAQ:AXLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Sutro Biopharma and Axcella Health's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sutro Biopharma and Axcella Health, as provided by MarketBeat.

Sutro Biopharma currently has a consensus price target of $23.3333, indicating a potential upside of 15.00%. Axcella Health has a consensus price target of $17.1250, indicating a potential upside of 210.80%. Given Axcella Health's stronger consensus rating and higher probable upside, analysts clearly believe Axcella Health is more favorable than Sutro Biopharma.

Volatility and Risk

Sutro Biopharma has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Axcella Health has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Institutional & Insider Ownership

78.8% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 66.8% of Axcella Health shares are owned by institutional investors. 28.9% of Sutro Biopharma shares are owned by company insiders. Comparatively, 10.4% of Axcella Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Sutro Biopharma and Axcella Health's top-line revenue, earnings per share and valuation.

Sutro Biopharma has higher revenue and earnings than Axcella Health. Sutro Biopharma is trading at a lower price-to-earnings ratio than Axcella Health, indicating that it is currently the more affordable of the two stocks.

Summary

Sutro Biopharma beats Axcella Health on 8 of the 13 factors compared between the two stocks.

Axcella Health (NASDAQ:AXLA) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Profitability

This table compares Axcella Health and Adaptimmune Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Axcella Health and Adaptimmune Therapeutics, as reported by MarketBeat.com.

Axcella Health currently has a consensus price target of $17.1250, indicating a potential upside of 210.80%. Adaptimmune Therapeutics has a consensus price target of $15.50, indicating a potential upside of 209.38%. Given Axcella Health's stronger consensus rating and higher probable upside, equities research analysts plainly believe Axcella Health is more favorable than Adaptimmune Therapeutics.

Risk and Volatility

Axcella Health has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500.

Institutional & Insider Ownership

66.8% of Axcella Health shares are owned by institutional investors. Comparatively, 99.8% of Adaptimmune Therapeutics shares are owned by institutional investors. 10.4% of Axcella Health shares are owned by insiders. Comparatively, 18.9% of Adaptimmune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Axcella Health and Adaptimmune Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Axcella Health has higher earnings, but lower revenue than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Axcella Health, indicating that it is currently the more affordable of the two stocks.

Summary

Adaptimmune Therapeutics beats Axcella Health on 7 of the 13 factors compared between the two stocks.

Axcella Health (NASDAQ:AXLA) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Profitability

This table compares Axcella Health and Vaxart's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Axcella Health and Vaxart, as reported by MarketBeat.com.

Axcella Health currently has a consensus price target of $17.1250, indicating a potential upside of 210.80%. Vaxart has a consensus price target of $15.00, indicating a potential upside of 153.38%. Given Axcella Health's higher probable upside, equities research analysts plainly believe Axcella Health is more favorable than Vaxart.

Risk and Volatility

Axcella Health has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Vaxart has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500.

Institutional & Insider Ownership

66.8% of Axcella Health shares are owned by institutional investors. Comparatively, 17.9% of Vaxart shares are owned by institutional investors. 10.4% of Axcella Health shares are owned by insiders. Comparatively, 7.3% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Axcella Health and Vaxart's top-line revenue, earnings per share (EPS) and valuation.

Vaxart has higher revenue and earnings than Axcella Health. Vaxart is trading at a lower price-to-earnings ratio than Axcella Health, indicating that it is currently the more affordable of the two stocks.

Summary

Axcella Health beats Vaxart on 8 of the 13 factors compared between the two stocks.